drugset / Trial / NCT04819581

Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects

NCT04819581

Phase 1 Completed 15 enrolled Scilex Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This study will assess the systemic exposure and pharmacokinetic parameters of SP-103 topical system following one, two, or three topical system applications and compare to the pharmacokinetics of ZTlido.

Timeline

Start
2019-08-03
Primary completion
2019-08-27
Completion
2019-08-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lidocaine Other / unclassified 1.8 % Topical
Subject SP-103 Unknown 5.4 % Topical

Indications

No indication recorded.